Bone marrow transplantation (BMT) for XXXX ( @entity3052 ) in first remission.

@entity1 @entity137 @entity786 @entity3052 @entity2132 @entity348 @entity401
20 @entity1 with @entity3052 ( @entity3052 ) in first remission were given @entity786 , 120 mg/kg, followed by @entity348 ( @entity348 ) and an HLA-identical allogeneic marrow transplant (BMT). @entity348 was delivered in a single dose (10 Gy on day -1) in 2 @entity1 , or in fractionated doses (3.3 rad/day on days -3, -2, -1) in 18 @entity1 . The median age of @entity1 was 22 years (range 2-44). Median time from remission to BMT was 5 months (range 1-12). 5 @entity1 died of transplant-related @entity137 ( @entity2132 with or without @entity401 ) and 15 are alive 7-77 months post-BMT (median 20). The actuarial 72 months survival is 73%. There has been one relapse in a 2-year-old @entity1 , 4 months post-BMT, in the marrow and in the testis. The 72-month actuarial disease-free survival is 68%. The actuarial probability of relapse is 7%. This study indicates that a high proportion of @entity3052 @entity1 treated in first remission with fractionated @entity348 and allogeneic marrow transplantation can become long-term disease-free survivors.
